4d
"I was fighting to survive": Patients still struggle with preauthorization despite promise of reform
Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, but patient advocates and medical providers remain skeptical.
SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. Learn more about ARGX stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results